TheraRadar
← Back
Data updated: Mar 29, 2026

ZHUHAI

OncologyOphthalmologyGastroenterology
Pharma

ZHUHAI is a pharmaceutical company focused on Oncology, Ophthalmology, Gastroenterology. Key products include BEIZRAY.

2024
Since
1
Drugs
-
Trials
2
Approved (2yr)

Key Drugs

BEIZRAY
docetaxel
Oncology
5 indications · 2024

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BEIZRAY 2025-04-22
Labeling
BEIZRAY 2024-10-23
Type 5 - New Formulation or New Manufacturer
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 31%
1 drugs Phase 1: 5
Ophthalmology 26%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1
Gastroenterology 23%
1 drugs Phase 2: 1
Infectious Disease 20%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
Baxter specialty
Infectious Disease, Oncology, Ophthalmology
AbbVie big-pharma
Oncology, Infectious Disease, Ophthalmology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease
FOUGERA PHARMS other
Ophthalmology, Infectious Disease, Oncology